BioPharmSignal logoBioPharmSignal

Biotech News

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Seres Therapeutics (MCRB)Seres TherapeuticsCompany update

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in shaping outcomes in IBD and immunocompromised patients CAMBRIDGE, Mass., April

Related news

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-06-25 11:00 EST

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

View all latest news

Seres Therapeutics

Live Biotherapeutic Platform Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science. SER-155 SER-155 is...

Recent company news

MCRBSeres Therapeutics2026-08-05 11:00 EST

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-06-25 11:00 EST

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

MCRBSeres Therapeutics2026-06-05 11:00 EST

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

MCRBSeres Therapeutics2026-05-12 11:00 EST

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Stock data

Close
4.82 USD
Market cap
70.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States